Provenge Outcomes Data "Moderately" Strong For Labeled Use; Off-Label Insufficient, AHRQ Tech Assessment Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Clinical research demonstrating positive health outcomes from Dendreon's prostate cancer vaccine Provenge is "moderately" strong, the Agency for Healthcare Research and Quality concludes in a draft technology assessment prepared for the upcoming meeting of the Medicare Evidence Development and Coverage Advisory Committee.
You may also be interested in...
Provenge Coverage With Data Collection Suggested By MEDCAC Members
The Centers for Medicare and Medicaid Services got a number of suggestions about linking Medicare coverage with data collection for Dendreon’s therapeutic prostate cancer vaccine Provenge at the Medicare Evidence Development and Coverage Advisory Committee’s Nov. 17 meeting.
Provenge Coverage With Data Collection Suggested By MEDCAC Members
The Centers for Medicare and Medicaid Services got a number of suggestions about linking Medicare coverage with data collection for Dendreon’s therapeutic prostate cancer vaccine Provenge at the Medicare Evidence Development and Coverage Advisory Committee’s Nov. 17 meeting.
Is Provenge "Reasonable And Necessary"? CMS Analysis For Medicare Coverage Seeks To Find Out
The Centers for Medicare and Medicaid Services may consider setting formal parameters around Medicare coverage for Dendreon's ground-breaking prostate cancer vaccine Provenge next year.